In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.
And, in March 2024, the FDA granted breakthrough designation for Mind Medicines (MindMed), MM120, (LSD D-tartrate) for the treatment of generalised anxiety disorder (GAD). In April 2024 ...
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for ...
After hours: 7:52:21 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback